.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
Novartis
Harvard Business School
Express Scripts
McKesson
Johnson and Johnson
McKinsey
Queensland Health
Cantor Fitzgerald
Farmers Insurance

Generated: December 14, 2017

DrugPatentWatch Database Preview

CRIXIVAN Drug Profile

« Back to Dashboard

Which patents cover Crixivan, and what generic alternatives are available?

Crixivan is a drug marketed by Merck Sharp Dohme and is included in one NDA. There are two patents protecting this drug.

This drug has forty-two patent family members in thirty-five countries.

The generic ingredient in CRIXIVAN is indinavir sulfate. There are two drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the indinavir sulfate profile page.
Drug patent expirations by year for CRIXIVAN

Pharmacology for CRIXIVAN

Medical Subject Heading (MeSH) Categories for CRIXIVAN

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
Merck Sharp DohmeCRIXIVANindinavir sulfateCAPSULE;ORAL020685-006Apr 19, 2000DISCNNoNo► Subscribe► Subscribe► SubscribeY► Subscribe
Merck Sharp DohmeCRIXIVANindinavir sulfateCAPSULE;ORAL020685-001Mar 13, 1996RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Merck Sharp DohmeCRIXIVANindinavir sulfateCAPSULE;ORAL020685-003Mar 13, 1996RXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Merck Sharp DohmeCRIXIVANindinavir sulfateCAPSULE;ORAL020685-001Mar 13, 1996RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Merck Sharp DohmeCRIXIVANindinavir sulfateCAPSULE;ORAL020685-006Apr 19, 2000DISCNNoNo► Subscribe► Subscribe► Subscribe► Subscribe
Merck Sharp DohmeCRIXIVANindinavir sulfateCAPSULE;ORAL020685-003Mar 13, 1996RXYesNo► Subscribe► Subscribe► SubscribeY► Subscribe
Merck Sharp DohmeCRIXIVANindinavir sulfateCAPSULE;ORAL020685-005Dec 17, 1998DISCNNoNo► Subscribe► Subscribe► Subscribe► Subscribe
Merck Sharp DohmeCRIXIVANindinavir sulfateCAPSULE;ORAL020685-005Dec 17, 1998DISCNNoNo► Subscribe► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: CRIXIVAN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Merck Sharp DohmeCRIXIVANindinavir sulfateCAPSULE;ORAL020685-001Mar 13, 1996► Subscribe► Subscribe
Merck Sharp DohmeCRIXIVANindinavir sulfateCAPSULE;ORAL020685-006Apr 19, 2000► Subscribe► Subscribe
Merck Sharp DohmeCRIXIVANindinavir sulfateCAPSULE;ORAL020685-005Dec 17, 1998► Subscribe► Subscribe
Merck Sharp DohmeCRIXIVANindinavir sulfateCAPSULE;ORAL020685-003Mar 13, 1996► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Premature patent expiration for: CRIXIVAN

Expiration due to failure to pay maintenance fee

Patent Number Tradename Expiration Date
► Subscribe CRIXIVAN ► Subscribe

International Patent Family for Tradename: CRIXIVAN

Country Document Number Estimated Expiration
Hungary9800810► Subscribe
Spain2200052► Subscribe
Norway973533► Subscribe
China1179722► Subscribe
Norway314568► Subscribe
World Intellectual Property Organization (WIPO)9623509► Subscribe
Czech Republic9702444► Subscribe
Germany69628819► Subscribe
JapanH10513186► Subscribe
Canada2211973► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Healthtrust
Fuji
Boehringer Ingelheim
Harvard Business School
Cipla
Chubb
Argus Health
Covington
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot